OCS-05 for Acute Optic Neuritis

OCS-05 for Acute Optic Neuritis
75%54%32%Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 26 • YES 68.0%Apr 27 • YES 68.0%Apr 28 • YES 64.5%Apr 29 • YES 64.5%Apr 30 • YES 63.0%May 1 • YES 61.6%May 2 • YES 61.6%May 3 • YES 60.3%May 4 • YES 60.3%May 5 • YES 60.3%May 7 • YES 44.7%May 12 • YES 39.2%May 13 • YES 39.2%
Oculis ($OCS)
No stock closeNo stock close$33.64$29.55$25.46Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 27 • OCS $27.12Apr 28 • OCS $26.72Apr 29 • OCS $26.45Apr 30 • OCS $27.48May 1 • OCS $27.48May 4 • OCS $28.26May 5 • OCS $27.75May 6 • OCS $29.58May 7 • OCS $31.09May 8 • OCS $32.64May 11 • OCS $32.65May 12 • OCS $30.41May 13 • OCS $31.37

Will this trial show a positive result on To describe the visual function on the 2.5% ETDRS Low Contrast Letter Acuity (LCVA) chart change from baseline (of the affected eye) to each time point (D15, M1, M3, M6)?

Paper Trading
Create account to trade
ClinicalTrialModel PositionsModel ReasoningOracle
Primary Completion
9/16/24
Study Completion
9/16/24
Sponsor
Oculis
Ticker
$OCS
Type
Phase 2
Trial Status
Completed
Trial Size
36
NCT
NCT04762017
Trial Description
OCS-05 added to standard corticosteroids was tested in adults with acute optic neuritis, mainly measuring abnormal changes in ECG heart-tracing results through Day 15.